<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9448730</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36068246</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">9448730</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">377</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41531-022-00377-w</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of healthy controls, PD-TD and PD-PIGD patients.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of healthy controls, PD-TD and PD-PIGD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>PD-TD subtype</th><th>PD-PIGD subtype</th><th>p: HC <italic>vs</italic> PD-TD</th><th>p: HC <italic>vs</italic> PD-PIGD</th><th>p: PD-PIGD <italic>vs</italic> PD-TD</th></tr><tr><th><italic>N</italic></th><th>60</th><th>32</th><th>26</th><th/><th/><th/></tr></thead><tbody><tr><td colspan="7"><italic>Demographic and general clinical variables</italic></td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.9 (46.14–77.72)</td><td>60.96 ± 7.22 (43.43–75.87)</td><td>61.73 ± 5.28 (48.45–71.42)</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>Sex [men/women]</td><td>29 (48.3)/31 (51.7)</td><td>19 (59.4)/13 (40.6)</td><td>10 (38.5)/16 (61.5)</td><td>0.38</td><td>0.48</td><td>0.19</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>12.88 ± 2.69 (7.00–20.00)</td><td>12.62 ± 2.65 (8.00–17.00)</td><td>0.84</td><td>0.47</td><td>1.00</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92)/4 (8)/0 (0)</td><td>31 (96.9)/1 (3.1)/0(0)</td><td>26 (92.0)/0 (0)/0 (0)</td><td>0.64</td><td>0.29</td><td>1.00</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>59.13 ± 7.66 (42.50–73.00)</td><td>58.54 ± 6.23 (42.00–70.00)</td><td>–</td><td>–</td><td>0.75</td></tr><tr><td>PD duration [years]</td><td>–</td><td>1.83 ± 1.74 (0.14–7.57)</td><td>3.20 ± 4.74 (0.00–23.94)</td><td>–</td><td>–</td><td>0.14</td></tr><tr><td>Family history [No/Yes]</td><td>–</td><td>22 (68.8)/10 (31.3)</td><td>22 (84.6)/4 (15.4)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>Side of onset [right/left/both]</td><td>–</td><td>20 (62.5)/12 (37.5)/0(0)</td><td>16 (61.5)/10 (38.5)/3 (3.3)</td><td>–</td><td>–</td><td>1.00</td></tr><tr><td>Levodopa equivalent daily dose [mg]</td><td>–</td><td>252.97 ± 266.97 (0.00–970.00)</td><td>342.60 ± 233.38 (0.00–1000.00)</td><td>–</td><td>–</td><td>0.18</td></tr><tr><td colspan="7"><italic>Clinical motor variables</italic></td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>1.16 ± 0.47 (1.00–3.00)</td><td>1.12 ± 0.43 (1.00–3.00)</td><td>–</td><td>–</td><td>0.73</td></tr><tr><td>UPDRS Total</td><td>–</td><td>28.53 ± 15.43 (11.00–81.00)</td><td>31.00 ± 11.82 (17.00–76.00)</td><td>–</td><td>–</td><td>0.51</td></tr><tr><td>UPDRS II Total</td><td>–</td><td>5.72 ± 4.38 (0.00–19.00)</td><td>7.12 ± 4.01 (2.00–20.00)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>UPDRS III Total</td><td>–</td><td>17.88 ± 10.18 (10.00–52.00)</td><td>17.96 ± 8.77 (10.00–52.00)</td><td>–</td><td>–</td><td>0.97</td></tr><tr><td><italic>UPDRS III Axial</italic></td><td>–</td><td>1.53 ± 1.50 (0.00–7.00)</td><td>2.58 ± 1.30 (1.00–7.00)</td><td>–</td><td>–</td><td><bold>0.01</bold></td></tr><tr><td><italic>UPDRS III Bradykinesia</italic></td><td>–</td><td>7.31 ± 5.27 (3.00–25.00)</td><td>8.92 ± 5.11 (5.00–27.00)</td><td>–</td><td>–</td><td>0.25</td></tr><tr><td><italic>UPDRS III Rigidity</italic></td><td>–</td><td>2.63 ± 1.62 (0.00–8.00)</td><td>3.89 ± 2.36 (2.00–13.00)</td><td>–</td><td>–</td><td><bold>0.02</bold></td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>0.22 ± 0.94 (0.00–5.00)</td><td>0.27 ± 0.96 (0.00–4.00)</td><td>–</td><td>–</td><td>0.84</td></tr><tr><td><italic>UPDRS IV Dyskinesia</italic> [No/Yes]</td><td>–</td><td>31 (96.9)/1 (3.1)</td><td>24 (92.3)/2 (7.7)</td><td>–</td><td>–</td><td>0.53</td></tr><tr><td><italic>UPDRS IV Fluctuation</italic> [No/Yes]</td><td>–</td><td>30 (93.8)/2 (6.3)</td><td>24 (92.3)/2 (7.7)</td><td>–</td><td>–</td><td>0.50</td></tr><tr><td>FOG-Q</td><td>–</td><td>0.69 ± 1.03 (0.00–4.00)</td><td>1.15 ± 1.43 (0.00–5.00)</td><td>–</td><td>–</td><td>0.16</td></tr></tbody></table><table-wrap-foot><p>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between PD patients and healthy controls and between PD groups were assessed using one-way ANOVA (for continuous demographic and general clinical variables) and Chi-square test (for all categorical variables). <italic>P</italic>-values were adjusted for multiple comparisons.</p><p><italic>FOG-Q</italic> freezing of gait questionnaire, <italic>HC</italic> healthy controls, <italic>N</italic> number, <italic>PD</italic> Parkinson’s disease, <italic>PIGD</italic> Postural Instability/Gait Disorder dominant phenotype, <italic>TD</italic> Tremor dominant phenotype, <italic>UPDRS</italic> Unified Parkinson’s Disease Rating Scale.</p><p>Bold values indicates statistical significant values.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of healthy controls, PD-TD and PD-PIGD patients.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>PD-TD subtype</th><th>PD-PIGD subtype</th><th>p: HC vs PD-TD</th><th>p: HC vs PD-PIGD</th><th>p: PD-PIGD vs PD-TD</th></tr><tr><th>N</th><th>60</th><th>32</th><th>26</th><th/><th/><th/></tr></thead><tbody><tr><td colspan="7">Demographic and general clinical variables</td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.9 (46.14–77.72)</td><td>60.96 ± 7.22 (43.43–75.87)</td><td>61.73 ± 5.28 (48.45–71.42)</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>Sex [men/women]</td><td>29 (48.3)/31 (51.7)</td><td>19 (59.4)/13 (40.6)</td><td>10 (38.5)/16 (61.5)</td><td>0.38</td><td>0.48</td><td>0.19</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>12.88 ± 2.69 (7.00–20.00)</td><td>12.62 ± 2.65 (8.00–17.00)</td><td>0.84</td><td>0.47</td><td>1.00</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92)/4 (8)/0 (0)</td><td>31 (96.9)/1 (3.1)/0(0)</td><td>26 (92.0)/0 (0)/0 (0)</td><td>0.64</td><td>0.29</td><td>1.00</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>59.13 ± 7.66 (42.50–73.00)</td><td>58.54 ± 6.23 (42.00–70.00)</td><td>–</td><td>–</td><td>0.75</td></tr><tr><td>PD duration [years]</td><td>–</td><td>1.83 ± 1.74 (0.14–7.57)</td><td>3.20 ± 4.74 (0.00–23.94)</td><td>–</td><td>–</td><td>0.14</td></tr><tr><td>Family history [No/Yes]</td><td>–</td><td>22 (68.8)/10 (31.3)</td><td>22 (84.6)/4 (15.4)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>Side of onset [right/left/both]</td><td>–</td><td>20 (62.5)/12 (37.5)/0(0)</td><td>16 (61.5)/10 (38.5)/3 (3.3)</td><td>–</td><td>–</td><td>1.00</td></tr><tr><td>Levodopa equivalent daily dose [mg]</td><td>–</td><td>252.97 ± 266.97 (0.00–970.00)</td><td>342.60 ± 233.38 (0.00–1000.00)</td><td>–</td><td>–</td><td>0.18</td></tr><tr><td colspan="7">Clinical motor variables</td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>1.16 ± 0.47 (1.00–3.00)</td><td>1.12 ± 0.43 (1.00–3.00)</td><td>–</td><td>–</td><td>0.73</td></tr><tr><td>UPDRS Total</td><td>–</td><td>28.53 ± 15.43 (11.00–81.00)</td><td>31.00 ± 11.82 (17.00–76.00)</td><td>–</td><td>–</td><td>0.51</td></tr><tr><td>UPDRS II Total</td><td>–</td><td>5.72 ± 4.38 (0.00–19.00)</td><td>7.12 ± 4.01 (2.00–20.00)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>UPDRS III Total</td><td>–</td><td>17.88 ± 10.18 (10.00–52.00)</td><td>17.96 ± 8.77 (10.00–52.00)</td><td>–</td><td>–</td><td>0.97</td></tr><tr><td>UPDRS III Axial</td><td>–</td><td>1.53 ± 1.50 (0.00–7.00)</td><td>2.58 ± 1.30 (1.00–7.00)</td><td>–</td><td>–</td><td>0.01</td></tr><tr><td>UPDRS III Bradykinesia</td><td>–</td><td>7.31 ± 5.27 (3.00–25.00)</td><td>8.92 ± 5.11 (5.00–27.00)</td><td>–</td><td>–</td><td>0.25</td></tr><tr><td>UPDRS III Rigidity</td><td>–</td><td>2.63 ± 1.62 (0.00–8.00)</td><td>3.89 ± 2.36 (2.00–13.00)</td><td>–</td><td>–</td><td>0.02</td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>0.22 ± 0.94 (0.00–5.00)</td><td>0.27 ± 0.96 (0.00–4.00)</td><td>–</td><td>–</td><td>0.84</td></tr><tr><td>UPDRS IV Dyskinesia [No/Yes]</td><td>–</td><td>31 (96.9)/1 (3.1)</td><td>24 (92.3)/2 (7.7)</td><td>–</td><td>–</td><td>0.53</td></tr><tr><td>UPDRS IV Fluctuation [No/Yes]</td><td>–</td><td>30 (93.8)/2 (6.3)</td><td>24 (92.3)/2 (7.7)</td><td>–</td><td>–</td><td>0.50</td></tr><tr><td>FOG-Q</td><td>–</td><td>0.69 ± 1.03 (0.00–4.00)</td><td>1.15 ± 1.43 (0.00–5.00)</td><td>–</td><td>–</td><td>0.16</td></tr></tbody></table></div>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between PD patients and healthy controls and between PD groups were assessed using one-way ANOVA (for continuous demographic and general clinical variables) and Chi-square test (for all categorical variables). P-values were adjusted for multiple comparisons.FOG-Q freezing of gait questionnaire, HC healthy controls, N number, PD Parkinson’s disease, PIGD Postural Instability/Gait Disorder dominant phenotype, TD Tremor dominant phenotype, UPDRS Unified Parkinson’s Disease Rating Scale.Bold values indicates statistical significant values.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Demographic and clinical characteristics of healthy controls, cPD-TD and ncPD-TD patients.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Demographic and clinical characteristics of healthy controls, cPD-TD and ncPD-TD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>ncPD-TD subtype</th><th>cPD-TD subtype</th><th>p:HC <italic>vs</italic> ncPD-TD</th><th>p:HC <italic>vs</italic> cPD-TD</th><th>p:ncPD-TD <italic>vs</italic> cPD-TD</th></tr><tr><th><italic>N</italic></th><th>60</th><th>18</th><th>10</th><th/><th/><th/></tr></thead><tbody><tr><td colspan="7"><italic>Demographic and general clinical variables</italic></td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.9 (46.14–77.72)</td><td>60.31 ± 7.98 (43.43–75.87)</td><td>60.69 ± 8.22 (46.46–73.53)</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>Sex [men/women]</td><td>29 (48.3)/31 (51.7)</td><td>12 (70.0)/6 (30.0)</td><td>4 (70.0)/6 (30.0)</td><td>0.91</td><td>0.74</td><td>0.24</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>13.17 ± 2.77 (7.00–20.00)</td><td>12.30 ± 2.75 (8.00–16.00)</td><td>1.00</td><td>0.56</td><td>1.00</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92.0)/4 (8.0)/0 (0.0)</td><td>18 (100.00)/0 (0.0)/0 (0.0)</td><td>9 (90.0)/1 (10.0)/0 (0.0)</td><td>0.57</td><td>1.00</td><td>0.36</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>58.75 ± 7.74 (42.50–73.00)</td><td>57.90 ± 8.16 (42.00–70.00)</td><td>–</td><td>–</td><td>0.79</td></tr><tr><td>PD duration [years]</td><td>–</td><td>1.56 ± 1.49 (0.14–5.30)</td><td>2.79 ± 2.11 (0.28–7.58)</td><td>–</td><td>–</td><td>0.08</td></tr><tr><td>Family history [No/Yes]</td><td>–</td><td>13 (72.2)/5 (27.8)</td><td>7 (70.0)/3(30.0)</td><td>–</td><td>–</td><td>1.00</td></tr><tr><td>Side of onset [right/left/both]</td><td>–</td><td>12 (66.7)/6 (33.3)/0(0.0)</td><td>4 (40.0)/3 (30.0)/0 (0.0)</td><td>–</td><td>–</td><td>0.24</td></tr><tr><td>Levodopa equivalent daily dose [mg]</td><td>–</td><td>179.17 ± 208.10 (0.00–740.00)</td><td>383.00 ± 342.38 (0.00–970.00)</td><td>–</td><td>–</td><td>0.06</td></tr><tr><td colspan="7"><italic>Clinical motor variables</italic></td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>1.03 ± 0.12 (1.00–1.50)</td><td>1.45 ± 0.76 (1.00–3.00)</td><td>–</td><td>–</td><td><bold>0.03</bold></td></tr><tr><td>UPDRS total</td><td>–</td><td>25.17 ± 9.28 (11.0–47.00)</td><td>38.00 ± 22.02 (12.00–81.00)</td><td>–</td><td>–</td><td><bold>0.04</bold></td></tr><tr><td>UPDRS II Total</td><td>–</td><td>5.11 ± 4.13 (0.00–19.00)</td><td>7.30 ± 5.01 (0.00–16.00)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>UPDRS III Total</td><td>–</td><td>15.89 ± 3.36 (10.00–23.00)</td><td>23.70 ± 16.55 (10.00–52.00)</td><td>–</td><td>–</td><td>0.06</td></tr><tr><td><italic>UPDRS III Axial</italic></td><td>–</td><td>1.39 ± 0.92 (0.00–3.00)</td><td>2.20 ± 2.25 (0.00–7.00)</td><td>–</td><td>–</td><td>0.19</td></tr><tr><td><italic>UPDRS III Bradykinesia</italic></td><td>–</td><td>5.5 ± 1.65 (3.00–8.00)</td><td>11.20 ± 8.09 (5.00–25.00)</td><td>–</td><td>–</td><td><bold>0.01</bold></td></tr><tr><td><italic>UPDRS III Rigidity</italic></td><td>–</td><td>2.22 ± 0.73 (0.00–3.00)</td><td>3.60 ± 2.56 (1.00–8.00)</td><td>–</td><td>–</td><td><bold>0.04</bold></td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>0.00 ± 0.00 (0.00–0.00)</td><td>0.70 ± 1.64 (0.00–5.00)</td><td>–</td><td>–</td><td>0.08</td></tr><tr><td><italic>UPDRS IV Dyskinesia</italic> [No/Yes]</td><td>–</td><td>18 (100)/0 (0)</td><td>9 (90)/1 (10)</td><td>–</td><td>–</td><td>0.36</td></tr><tr><td><italic>UPDRS IV Fluctuation</italic> [No/Yes]</td><td>–</td><td>18 (100)/0 (0)</td><td>8 (80)/2 (20)</td><td>–</td><td>–</td><td>0.24</td></tr><tr><td>FOG-Q</td><td>–</td><td>0.28 ± 0.46 (0.00–1.00)</td><td>1.50 ± 1.43 (0.00–4.00)</td><td>–</td><td>–</td><td><bold>0.002</bold></td></tr></tbody></table><table-wrap-foot><p>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between PD patients and healthy controls and between PD-TD subtypes were assessed using one-way ANOVA (for continuous demographic and general clinical variables) and Chi-squared test (for all categorical variables). <italic>P</italic>-values were adjusted for multiple comparisons.</p><p><italic>c</italic> converter, <italic>FOG-Q</italic> freezing of gait questionnaire, <italic>HC</italic> healthy controls, <italic>N</italic> number, <italic>nc</italic> non-converter, <italic>PD</italic> Parkinson’s disease, <italic>TD</italic> Tremor dominant phenotype, <italic>UPDRS</italic> Unified Parkinson’s Disease Rating Scale.</p><p>Bold values indicates statistical significant values.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of healthy controls, cPD-TD and ncPD-TD patients.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variables</th><th>HC</th><th>ncPD-TD subtype</th><th>cPD-TD subtype</th><th>p:HC vs ncPD-TD</th><th>p:HC vs cPD-TD</th><th>p:ncPD-TD vs cPD-TD</th></tr><tr><th>N</th><th>60</th><th>18</th><th>10</th><th/><th/><th/></tr></thead><tbody><tr><td colspan="7">Demographic and general clinical variables</td></tr><tr><td>Age at MRI [years]</td><td>61.79 ± 8.9 (46.14–77.72)</td><td>60.31 ± 7.98 (43.43–75.87)</td><td>60.69 ± 8.22 (46.46–73.53)</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>Sex [men/women]</td><td>29 (48.3)/31 (51.7)</td><td>12 (70.0)/6 (30.0)</td><td>4 (70.0)/6 (30.0)</td><td>0.91</td><td>0.74</td><td>0.24</td></tr><tr><td>Education [years]</td><td>13.52 ± 2.57 (8.00–16.00)</td><td>13.17 ± 2.77 (7.00–20.00)</td><td>12.30 ± 2.75 (8.00–16.00)</td><td>1.00</td><td>0.56</td><td>1.00</td></tr><tr><td>Handedness [right/left/both]</td><td>46 (92.0)/4 (8.0)/0 (0.0)</td><td>18 (100.00)/0 (0.0)/0 (0.0)</td><td>9 (90.0)/1 (10.0)/0 (0.0)</td><td>0.57</td><td>1.00</td><td>0.36</td></tr><tr><td>Age at onset [years]</td><td>–</td><td>58.75 ± 7.74 (42.50–73.00)</td><td>57.90 ± 8.16 (42.00–70.00)</td><td>–</td><td>–</td><td>0.79</td></tr><tr><td>PD duration [years]</td><td>–</td><td>1.56 ± 1.49 (0.14–5.30)</td><td>2.79 ± 2.11 (0.28–7.58)</td><td>–</td><td>–</td><td>0.08</td></tr><tr><td>Family history [No/Yes]</td><td>–</td><td>13 (72.2)/5 (27.8)</td><td>7 (70.0)/3(30.0)</td><td>–</td><td>–</td><td>1.00</td></tr><tr><td>Side of onset [right/left/both]</td><td>–</td><td>12 (66.7)/6 (33.3)/0(0.0)</td><td>4 (40.0)/3 (30.0)/0 (0.0)</td><td>–</td><td>–</td><td>0.24</td></tr><tr><td>Levodopa equivalent daily dose [mg]</td><td>–</td><td>179.17 ± 208.10 (0.00–740.00)</td><td>383.00 ± 342.38 (0.00–970.00)</td><td>–</td><td>–</td><td>0.06</td></tr><tr><td colspan="7">Clinical motor variables</td></tr><tr><td>Hoehn &amp; Yahr</td><td>–</td><td>1.03 ± 0.12 (1.00–1.50)</td><td>1.45 ± 0.76 (1.00–3.00)</td><td>–</td><td>–</td><td>0.03</td></tr><tr><td>UPDRS total</td><td>–</td><td>25.17 ± 9.28 (11.0–47.00)</td><td>38.00 ± 22.02 (12.00–81.00)</td><td>–</td><td>–</td><td>0.04</td></tr><tr><td>UPDRS II Total</td><td>–</td><td>5.11 ± 4.13 (0.00–19.00)</td><td>7.30 ± 5.01 (0.00–16.00)</td><td>–</td><td>–</td><td>0.22</td></tr><tr><td>UPDRS III Total</td><td>–</td><td>15.89 ± 3.36 (10.00–23.00)</td><td>23.70 ± 16.55 (10.00–52.00)</td><td>–</td><td>–</td><td>0.06</td></tr><tr><td>UPDRS III Axial</td><td>–</td><td>1.39 ± 0.92 (0.00–3.00)</td><td>2.20 ± 2.25 (0.00–7.00)</td><td>–</td><td>–</td><td>0.19</td></tr><tr><td>UPDRS III Bradykinesia</td><td>–</td><td>5.5 ± 1.65 (3.00–8.00)</td><td>11.20 ± 8.09 (5.00–25.00)</td><td>–</td><td>–</td><td>0.01</td></tr><tr><td>UPDRS III Rigidity</td><td>–</td><td>2.22 ± 0.73 (0.00–3.00)</td><td>3.60 ± 2.56 (1.00–8.00)</td><td>–</td><td>–</td><td>0.04</td></tr><tr><td>UPDRS IV Total</td><td>–</td><td>0.00 ± 0.00 (0.00–0.00)</td><td>0.70 ± 1.64 (0.00–5.00)</td><td>–</td><td>–</td><td>0.08</td></tr><tr><td>UPDRS IV Dyskinesia [No/Yes]</td><td>–</td><td>18 (100)/0 (0)</td><td>9 (90)/1 (10)</td><td>–</td><td>–</td><td>0.36</td></tr><tr><td>UPDRS IV Fluctuation [No/Yes]</td><td>–</td><td>18 (100)/0 (0)</td><td>8 (80)/2 (20)</td><td>–</td><td>–</td><td>0.24</td></tr><tr><td>FOG-Q</td><td>–</td><td>0.28 ± 0.46 (0.00–1.00)</td><td>1.50 ± 1.43 (0.00–4.00)</td><td>–</td><td>–</td><td>0.002</td></tr></tbody></table></div>Values are reported as mean ± standard deviation (range) or absolute and percentage frequency (%) for continuous and categorical variables, respectively. Differences between PD patients and healthy controls and between PD-TD subtypes were assessed using one-way ANOVA (for continuous demographic and general clinical variables) and Chi-squared test (for all categorical variables). P-values were adjusted for multiple comparisons.c converter, FOG-Q freezing of gait questionnaire, HC healthy controls, N number, nc non-converter, PD Parkinson’s disease, TD Tremor dominant phenotype, UPDRS Unified Parkinson’s Disease Rating Scale.Bold values indicates statistical significant values.</transformed-table></extracted-table></extracted-tables-set>